Last reviewed · How we verify
A Comparison of the Efficacy of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 Inhalation b.i.d. Plus As-needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26 Weeks, Randomised, Open-label, Parallel-group, Multicentre Study
The purpose of the study is to compare the efficacy of a flexible dose of Symbicort with conventional stepwise treatment according to asthma treatment guidelines in patients with persistent asthma
Details
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 1000 |
| Start date | 2005-07 |
| Completion | 2006-12 |
Conditions
- Asthma
Interventions
- Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy
Primary outcomes
- Time to first severe asthma exacerbation
Countries
Chile, Croatia, Czechia, Greece, Iceland, Latvia, Lithuania, Portugal, Slovakia, Slovenia